Lappe Mark — SEC Form 4 filings
SEC reporting owner CIK 1366074. 7 Form 4 filings on record with FilingPulse; latest filed 2026-09-08.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-05-30 to 2026-09-08. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 17 legs across 5 filings — 189,000 shares, $5,060,711 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 9.
- Largest priced transaction: purchase of 9,681 shares @ $112.28 ($1,087,001) in Inhibrx Biosciences, Inc., filed 2026-09-08.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | Chief Executive Officer, Director | 6 | 17 legs · 189,000 sh · $5,060,711 | — | 4 |
| Inhibrx, Inc. (INBX) | Chief Executive Officer, Director | 1 | — | — | 5 |
Form 4 filings — Lappe Mark
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-08 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 5,895 @ $99.29 · Purchase (P): 6,605 @ $100.64 · Purchase (P): 1,100 @ $107.12 · Purchase (P): 500 @ $108.23 · Purchase (P): 1,219 @ $111.88 · Purchase (P): 9,681 @ $112.28 | EDGAR |
| 2024-09-16 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 26,963 @ $15.05 · Purchase (P): 13,037 @ $17.13 | EDGAR |
| 2024-09-10 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 26,000 @ $15.29 · Purchase (P): 9,500 @ $15.21 · Purchase (P): 8,500 @ $15.19 | EDGAR |
| 2024-09-03 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 10,000 @ $14.03 · Purchase (P): 10,000 @ $14.02 · Purchase (P): 15,288 @ $15.66 · Purchase (P): 4,712 @ $16.31 | EDGAR |
| 2024-08-22 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 27,055 @ $12.97 · Purchase (P): 12,945 @ $12.93 | EDGAR |
| 2024-05-30 | 4 | Inhibrx, Inc. (INBX) | Disposition to issuer (D): 2,486,192 @ $30 · Disposition to issuer (D): 500,000 @ $30 · Disposition to issuer (D): 59,462 @ $30 · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 145,000 (derivative) | EDGAR |
| 2024-05-30 | 4 | Inhibrx Biosciences, Inc. (INXB) | Grant/award (A): 621,548 · Grant/award (A): 125,000 · Grant/award (A): 14,865 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1366074 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →